Scarica l'app Stockscreener
37.42
1.27%
-0.48
Dopo l'orario di chiusura:
37.25
-0.17
-0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$37.90
Aprire:
$37.78
Volume 24 ore:
2.59M
Relative Volume:
0.81
Capitalizzazione di mercato:
$10.07B
Reddito:
$2.17B
Utile/perdita netta:
$521.27M
Rapporto P/E:
21.14
EPS:
1.77
Flusso di cassa netto:
$633.79M
1 W Prestazione:
-3.13%
1M Prestazione:
+1.30%
6M Prestazione:
-0.61%
1 anno Prestazione:
+43.81%
Intervallo 1D:
$37.25
$38.00
Intervallo di 1 settimana:
$37.25
$38.95
Portata 52W:
$25.12
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Confronta EXEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
37.42 | 10.20B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis, Inc. (EXEL) Halts Phase 3 STELLAR-305 Trial - MSN
Exelixis Announces New Executive VP for R&D - MSN
What candlestick patterns are forming on Exelixis Inc.Weekly Volume Report & Fast Entry and Exit Trade Plans - Newser
Signal strength of Exelixis Inc. stock in tech scannersMarket Risk Analysis & Weekly Watchlist of Top Performers - Newser
Will breakout in Exelixis Inc. lead to full recoveryForecast Cut & Safe Capital Allocation Plans - Newser
Exelixis Inc. stock retracement – recovery analysisInflation Watch & Free Risk Controlled Daily Trade Plans - Newser
Developing predictive dashboards with Exelixis Inc. dataMarket Movement Recap & Free Technical Pattern Based Buy Signals - Newser
Building trade automation scripts for Exelixis Inc.Market Movers & Weekly Consistent Profit Watchlists - Newser
Should you wait for a breakout in Exelixis Inc.Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Can Exelixis Inc. recover in the next quarterWeekly Trend Recap & Real-Time Volume Spike Alerts - Newser
Sector ETF performance correlation with Exelixis Inc.July 2025 Reactions & Free Daily Entry Point Trade Alerts - Newser
Full technical analysis of Exelixis Inc. stockJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - Newser
How to interpret RSI for Exelixis Inc. stockM&A Rumor & Short-Term High Return Strategies - Newser
What Fibonacci levels say about Exelixis Inc. reboundJuly 2025 Opening Moves & Real-Time Buy Signal Alerts - Newser
Statistical indicators supporting Exelixis Inc.’s strengthJuly 2025 Price Swings & Breakout Confirmation Alerts - Newser
Exelixis Appoints New Executive VP for R&D Amid Leadership Transition - AInvest
Will Exelixis Inc. stock go up soonMarket Volume Summary & AI Driven Stock Movement Reports - Newser
Identifying reversal signals in Exelixis Inc.2025 Technical Overview & Expert Verified Stock Movement Alerts - Newser
Is Exelixis Inc. stock bottoming outJuly 2025 Setups & Verified Momentum Stock Watchlist - Newser
Exelixis' Strategic R&D Leadership Transition: Balancing Continuity and Innovation Amid Restructuring - AInvest
It's A Story Of Risk Vs Reward With Exelixis, Inc. (NASDAQ:EXEL) - 富途牛牛
Exelixis' Strategic R&D Leadership Transition: A Catalyst for Long-Term Oncology Innovation and Shareholder Value - AInvest
Exelixis announces leadership changes with new executive appointments - Investing.com
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development | EXEL Stock News - GuruFocus
Exelixis's R&D Leadership Restructuring: A Strategic Move for Sustained Innovation in Oncology? - AInvest
Exelixis Names Dana T. Aftab as Executive Vice President of Research and Development. - AInvest
Exelixis, Inc. Appoints Dana T. Aftab as Its Executive Vice President, Research and Development - MarketScreener
Bay Area biotech company worth $10 billion lays off 130 workers - SFGATE
Do Options Traders Know Something About Exelixis Stock We Don't? - sharewise.com
Exelixis Stock Implied Volatility Suggests Big Move Ahead - AInvest
Building trade automation scripts for Exelixis IncMarket Activity Recap & AI Optimized Trade Strategies - Newser
Exelixis’s Promising Study on Renal Cell Carcinoma: A Potential Game Changer? - MSN
How to manage a losing position in Exelixis Inc.2025 Technical Overview & Free Fast Entry Momentum Trade Alerts - Newser
Exelixis Q2 net product revenues miss consensus estimate by 2%. - AInvest
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.96%
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):